Investigational / not FDA-approved

PE-22-28

Shortened spadin / TREK-1 blocker class — preclinical antidepressant models; CID TBD.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. PE-22-28 is a shortened spadin analogue (sortilin / NTSR3 propeptide lineage) developed as a TREK-1 (K2P2.1) blocker with antidepressant-like activity in models. It is not a generic “PE” growth factor fragment, not PEG-MGF, and not PT-141. No clean PubChem CID was locked in this pass for the exact PE-22-28 sequence object — treat sequence / analogue naming as To be confirmed against the Djillani / Pietri primary papers before UI badges. This drawer marks papers. It is not use advice.

Bottom line

PubMed object-matched literature is small and preclinical / translational. Core paper Djillani 2017 characterizes shortened spadin analogues (including PE-22-28 framing) with TREK-1 inhibition, in vivo stability, and antidepressant-like activity. Related spadin / sortilin reviews and stroke-recovery / post-stroke depression protective reports expand the class but are not human PE-22-28 RCTs. No approved human antidepressant indication for PE-22-28 is assumed here.

Papers

PE-22-28 / shortened spadin core

PMID 28955242 — Djillani 2017

Tested: shortened spadin analogues (PE-22-28 lineage) with improved TREK-1 inhibition, in vivo stability, and antidepressant activity in animal models.

Does not show: a completed human Phase 3 antidepressant RCT for PE-22-28.

PMID 31325429 — Pietri 2019

Tested: protective effects of sortilin-derived peptides on stroke recovery and post-stroke depression models.

Does not show: that PE-22-28 is an approved post-stroke drug.

PMID 25080852 — Veyssiere 2015

Tested: retroinverso spadin analogues with increased antidepressant effects (related spadin chemistry).

Does not show: identity equivalence of every retroinverso analogue to PE-22-28.

PMID 30291907 — Djillani 2019

Tested: review of TREK-1 blockers for depression with focus on spadin.

Does not show: new primary human PE-22-28 efficacy data.

PMID 30670975 — Mazella 2018

Tested: sortilin/NTSR3 involvement in depression as progenitor of spadin and role in TREK-1 membrane expression.

Does not show: a human PE-22-28 trial.

PMID 27816451 — Hivelin 2017

Tested: sortilin-derived propeptide regulation during adipocyte differentiation and inflammation (class biology).

Does not show: PE-22-28 metabolic indication in humans.

What is not established

Human clinical efficacy for PE-22-28 as an antidepressant or post-stroke therapy. A locked PubChem CID / CAS for UI badges without sequence confirmation. Equivalence to PEG-MGF, PT peptides, or unrelated “PE-” shop SKUs. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

28955242 31325429 25080852 30291907 30670975 27816451

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.